FdaApplication
NDA 217180
Identifiers
- fda_app_no: NDA217180
Properties
| Property | Value |
|---|---|
| applicant_name | INCYTE CORP |
| application_type | NDA |
| approval_date | 2026-05-01 |
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| JAKAFI XR | RUXOLITINIB PHOSPHATE | EQ 33MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | EQ 22MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | EQ 55MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | EQ 11MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | EQ 44MG BASE | TABLET, EXTENDED RELEASE;ORAL |
5 products